BofA analyst Jason Gerberry raised the firm’s price target on Lenz Therapeutics (LENZ) to $53 from $44 and keeps a Buy rating on the shares. The firm cites the company’s Vizz FDA approval and Q2 report the target increase. It believes Lenz’s peak sales opportunity for Vizz is being underappreciated at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright
- Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential
- Lenz Therapeutics price target raised to $52 from $49 at Citi
- LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop
- Lenz Therapeutics announces FDA approval of Vizz eye drop